Irish researchers have developed an experimental messenger RNA (mRNA) vaccine that targets neuroblastoma, the deadliest solid cancer affecting children. The vaccine, tested at a preclinical stage, aims to mobilize the immune system against this aggressive tumor, opening a potential new treatment pathway for a disease that currently has limited therapeutic options.
Neuroblastoma is a cancer that develops from immature nerve cells and primarily affects infants and young children under the age of five. It accounts for approximately 15% of all childhood cancer deaths, making it one of the most challenging pediatric malignancies. The tumor often arises in the adrenal glands but can spread rapidly to lymph nodes, bone marrow, and other organs. Despite advances in chemotherapy, surgery, and radiation, the prognosis for high-risk neuroblastoma remains poor, with long-term survival rates below 50%.
The experimental vaccine, developed by a team at University College Dublin and the National Children's Research Centre in Ireland, uses mRNA technology similar to that employed in some COVID-19 vaccines. However, instead of encoding a viral protein, the vaccine instructs cells to produce specific proteins found on neuroblastoma cells. This trains the immune system to recognize and attack the cancer cells while sparing healthy tissue.
In preclinical studies, the vaccine demonstrated the ability to stimulate a strong immune response against neuroblastoma cells. The researchers reported that the treatment slowed tumor growth and improved survival in animal models. These findings, published in the journal Cancer Research, represent a significant step toward a potential clinical application for children with this devastating disease.
Dr. Olga Piskareva, a lead researcher on the project, emphasized the importance of developing targeted therapies for pediatric cancers. She noted that while mRNA vaccines have gained widespread attention for infectious diseases, their application in oncology, particularly for childhood cancers, remains an underexplored area. The neuroblastoma vaccine is designed to be personalized, potentially allowing customization based on the specific genetic mutations present in a patient's tumor.
The research team plans to advance the vaccine into clinical trials, pending regulatory approval and additional funding. If successful, the approach could be adapted to treat other pediatric solid tumors, such as Wilms tumor or certain sarcomas, which also lack effective targeted therapies. The study highlights the growing potential of mRNA technology beyond infectious disease, offering hope for patients with cancers that have historically been difficult to treat.
Neuroblastoma is classified into low, intermediate, and high-risk categories. High-risk neuroblastoma is particularly aggressive and often relapses after initial treatment. Current standard therapy includes intensive chemotherapy, surgery, stem cell transplantation, and immunotherapy with dinutuximab, a monoclonal antibody. However, these treatments carry significant side effects, and many children develop resistance. The mRNA vaccine approach aims to complement existing therapies by providing a more precise and durable immune attack.
The development of this vaccine also underscores the broader shift toward immunotherapy in pediatric oncology. Unlike traditional chemotherapy, which kills rapidly dividing cells indiscriminately, immunotherapies harness the patient's own immune system to target cancer specifically. This can reduce long-term toxicities, which are a major concern for young survivors who face lifelong health issues from aggressive treatments.
Experts caution that preclinical success does not guarantee effectiveness in humans, and the vaccine must undergo rigorous testing in clinical trials to assess safety and efficacy. However, the early results are promising and provide a foundation for further research. The Irish team is collaborating with international partners to accelerate the transition from laboratory to clinic.
If the vaccine proves safe and effective in human trials, it could become part of a new standard of care for high-risk neuroblastoma. The approach also aligns with the growing interest in personalized medicine, where treatments are tailored to the molecular profile of each patient's cancer. For families affected by neuroblastoma, the research offers a glimmer of hope in a field where progress has been slow.
The study was funded by the Irish Cancer Society and the Children's Health Foundation, reflecting a commitment to addressing pediatric cancer, which receives a fraction of the research funding allocated to adult cancers. The researchers hope that their work will inspire further investment in childhood cancer research and the development of innovative therapies.
